Partnerships & Mergers

Over the past five years, the collaboration has supported more than 1,300 WellSpan patients across 12 cancer subspecialties through physician consultations, multidisciplinary tumour conferences and access to Johns Hopkins subspecialists.

As part of the agreement, Charles River will use technologies such as next-generation sequencing (NGS) to support chemistry, manufacturing and controls (CMC) activities associated with the vaccine programme.

The collaboration will focus on designing next-generation photosensitisers for photodynamic therapy (PDT), a treatment that uses light-activated drugs to target and destroy tumour cells.

The device uses controlled freezing to adhere to and remove targeted tissue or foreign material, enabling clinicians to perform both diagnostic and therapeutic interventions through a bronchoscope.

The initiative aims to help patients with the greatest medical needs access modern therapies within a coordinated framework that complements the UAE’s national health insurance system.

Through the expanded partnership, Mayo Clinic will clinically integrate Exer AI’s hand and wrist module into its orthopaedic workflows to support musculoskeletal care.

The partnerships will enable healthcare providers to integrate wearable and out-of-hospital monitoring technologies into the Philips ecosystem.

Under the agreement, Ono will work with Mediar to identify potential treatments using the biotechnology company’s fibrosis-focused discovery platform and expertise in myofibroblast biology and fibrosis-related pathways.

The initiative supports Abu Dhabi’s broader strategy to use digital health technologies, real-world evidence and artificial intelligence to advance preventive and personalised healthcare.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.